3C-P

From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 3C-P
3C-P
3C-P.svg
Chemical Nomenclature
Common names 3C-P, 3C-Proscaline
Substitutive name 3,5-Dimethoxy-4-propoxyamphetamine
Systematic name 1-(4-Propoxy-3,5-dimethoxyphenyl)propan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold x"x" is not a number. mg
Light x"x" is not a number. - x"x" is not a number. mg
Common x"x" is not a number. - x"x" is not a number. mg
Strong x"x" is not a number. - x"x" is not a number. mg
Heavy x"x" is not a number. mg+
Duration
Total 10 - 16 hours
Onset 1 - 2 hours
Peak 4 - 8 hours
Offset 3 - 6 hours
After effects 3 - 6 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Cannabis
Stimulants
Tramadol
Lithium


Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

3,5-Dimethoxy-4-propoxyamphetamine (also known as 3C-P or 3C-Proscaline) is a lesser-known psychedelic substance of the amphetamine class. Although its name suggests it may be related to the 2C-x family, this is not the case since it is the 3-Carbon analog of proscaline.

The original synthesis date of 3C-P is unknown. Its theoretical synthesis is briefly mentioned in Alexander Shulgin's book PiHKAL, in which it is speculated to have psychedelic properties and a presumed dosage range of 20 to 40 milligrams.[1] It is typically sold on the online research chemical market.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 3C-P, and it has only a brief history of human usage. It is highly advised to use harm reduction practices if using this substance.

Chemistry

3C-P or 3,5-Dimethoxy-4-propoxyamphetamine, is a molecule of the substituted amphetamine class. Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα. 3C-P contains methoxy functional groups OCH3 attached to carbons R3 and R5 and a propoxy chain OCH2CH2CH3 attached to carbon R4 of the phenyl ring.

3C-P is the amphetamine analog of proscaline.

Pharmacology

Further information: Serotonergic psychedelic

Although its name suggests it may be related to the 2C-x family, this is not the case. 3C-P is actually the 3-Carbon analog of proscaline, thus the name.

Its pharmacology can provide strong interaction with 5-HT2A receptors, which could potentially help to prevent cluster headaches or give the compound the possibility to ease the psychological suffering associated with end-stage cancer.

3C-P's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

According to the structure-activity-relationship between mescaline analogues, 3C-P has been identified as being more potent than mescaline and TMA-2. It has similar potency in animal studies to 3C-E, and the authors of one study on potency of mescaline analogues in rats predict that it may have similar effects and dosage to 3C-E.[2]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.


Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 3C-P use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 3C-P is a research chemical with very little history of human usage.

Anecdotal evidence from people within the community who have tried 3C-P suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

3C-P is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 3C-P is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 3C-P presents cross-tolerance with all psychedelics, meaning that after the consumption of 3C-P all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[4]
  • United States: 3C-P is technically not scheduled in the United States, but could be considered an analog of mescaline and may, therefore, be considered a Schedule I drug under the Federal Analogue Act.
  • Japan: 3C-P is a controlled substance in Japan effective February 28th, 2018.[5]

See also

External links

References

Question book-new.svg

This article does not cite enough references.

You can help by adding some.

  1. https://erowid.org/library/books_online/pihkal/pihkal140.shtml
  2. Halberstadt, AL; Chatha, M; Chapman, SJ; Brandt, SD. Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. J. Psychopharmacol., 21 Feb 2019, 0269881119826610. 901 kB. https://doi.org/10.1177/0269881119826610
  3. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  4. Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
  5. 指定薬物を指定する省令が公布されました (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved May 2, 2022.